EUCTR2013-000493-30-ES进行中（未招募）1 期
A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid, versus masitinib alone, versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer - Colon II
AB Science0 个研究点目标入组 75 人开始时间: 2014年12月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient with non-resectable metastatic colorectal cancer with histological or cytological documentation of adenocarcinoma of the colon or rectum
- •2.Patient in third line or fourth line treatment for metastatic colorectal cancer
- •?in failure of all available therapies : 5FU, irinotecan, oxalplatin +/- bevacizumab,
- •?for which treatment by cetuximab or panatumumab is not recommended
- •?for which treatment by regorafenib is not recommended
- •3.Patient with measurable lesions according to RECIST criteria (version 1.1) with spiral CT scan and defined as ?10 mm in longest diameter and 2X the slice thickness for extra nodal lesions and/or >15 mm in short axis diameter for nodal lesions
- •4.Patient with ECOG ? 2
- •5.Patient with adequate organ function
- •?Absolute neutrophils count (ANC) ? 1.5 x 109/L
- •?Haemoglobin ? 10 g/dL
- •?Platelets (PLT) ? 75 x 109/L
- •?AST/ALT ? 3 x ULN (? 5 x ULN in case of liver metastases)
- •?Gamma GT ? 2.5 x ULN (? 5 x ULN in case of liver metastases)
- •?Bilirubin ? 1.5x ULN (? 3xULN in case of liver metastases)
- •?Normal Creatinine or if abnormal creatinine, creatinine clearance ? 50 mL/min (Cockcroft and Gault formula)
- •?Albumin > 1 x LLN
- •?Urea < 2 x ULN
- •?Proteinuria < 30 mg/dL (1+) on the dipstick. If proteinuria is ? 1+ on the dipstick, 24 hours proteinuria must be < 1.5g/24 hours
- •6.Patient with life expectancy > 3 months
- •7.Patient weight > 40 kg and BMI > 18 kg/m²
- •8.Female or male patient ? 18 years
- •9.Man and woman of childbearing potential, who agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake
- •10.Female patient of childbearing potential must have a negative pregnancy test at screening and baseline
- •11.Patient able and willing to comply with study visits and procedures as per protocol
- •12.Patient able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol-specific procedures are performed. If the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable, the designated legal guardian must sign the informed consent
- •13.Patient able to understand the patient card and to follow the patient card procedures, in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity during the first 2 months of treatment
- •14.Patient affiliated to a social security regimen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Prior treatment with masitinib, or any other tyrosine kinase inhibitor for the treatment of malignancy, except regorafenib,
- •2.More than 3 prior chemotherapy regimens for metastatic colorectal cancer.
- •3.Pregnant, intent to be pregnant, or nursing female patient
- •4.Patient with any chronic inflammatory bowel disease
- •5.Patient treated for a cancer other than colorectal cancer within five years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ
- •6.Patient with an hepatic involvement > 50%
- •7.Patient with active central nervous system (CNS) metastasis or history of CNS metastases.
- •8.Patient with an active infection (Human immunodeficiency virus infection and/or hepatitis B or C infection ?)
- •9.Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •?Patient with recent cardiac history (within 6 months) of:
- •-Acute coronary syndrome
- •-Acute heart failure (class III or IV of the NYHA classification)
- •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •?Patient with cardiac failure class III or IV of the NYHA classification
- •?Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •?Syncope without known aetiology within 3 months
- •?Uncontrolled severe hypertension, according to the judgement of the investigator, or symptomatic hypertension
- •10.Patient with a history of poor compliance or of drug/alcohol abuse, or excessive alcohol beverage consumption, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •11.Any previous treatment with an investigational agent or chemotherapy or biological agent will require a wash-out period of four weeks prior to baseline
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or Best suportiv care) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesMetastatic colorectal cancer after 2 or 3 previous lines of treatmentMedDRA version: 19.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2013-000493-30-CZAB Science150
进行中（未招募）
1 期
Evaluation of masitinib combined to gemcitabine, carboplatin or capecitabine in patients with a metastatic or locally advanced breast cancer relapsing after a first chemotherapy treatmentMetastatic or locally advanced breast cancerMedDRA version: 18.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864EUCTR2010-022646-24-ESAB Science60
进行中（未招募）
不适用
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or Best Supportive Care) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesMetastatic colorectal cancer after 2 or 3 previous lines of treatmentMedDRA version: 18.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2013-000493-30-GRAB Science120
进行中（未招募）
1 期
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or FOLFIRI alone) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesEUCTR2013-000493-30-SKAB Science150
尚未招募
2 期
A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen in HER2-negative inflammatory Breast CancerBreast cancer2024-514899-41-00Institut Paoli Calmettes72